期刊
EPILEPSIA
卷 52, 期 9, 页码 1750-1756出版社
WILEY
DOI: 10.1111/j.1528-1167.2011.03155.x
关键词
Epilepsy; Imaging; Guidelines
资金
- Lundbeck Inc.
- King Pharmaceuticals
- PRA International, Eisai Inc.
- Marinus Pharmaceuticals, Inc.
- NIH [NINDS] [1R01NS44280-01]
- NIH NICHD [1P30HD40677-01]
- NCRR [1K12RR17613-01]
- NIMH [1 R01 MH065395-01A2]
- CDC-APTR [R-03]
- National Institute for Health Research [NF-SI-0509-10161] Funding Source: researchfish
Recognition of limited economic resources, as well as potential adverse effects of over testing, has increased interest in evidence-based assessment of new medical technology. This creates a particular problem for evaluation and treatment of epilepsy, which are increasingly dependent on advanced imaging and electrophysiology, since there is a marked paucity of epilepsy diagnostic and prognostic studies that meet rigorous standards for evidence classification. The lack of high quality data reflects fundamental weaknesses in many imaging studies but also limitations in the assumptions underlying evidence classification schemes as they relate to epilepsy, and to the practicalities of conducting adequately powered studies of rapidly evolving technologies. We review the limitations of current guidelines and propose elements for imaging studies that can contribute meaningfully to the epilepsy literature.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据